AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2020
Mar 3, 2020
32254_dirs_2020-03-03_5dbf2aa4-f0f1-485e-ad27-dcf2ed64b622.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2020-02-28
Reporting Person: Elston George (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-02-28 | Stock Option (Right to Buy) | $1.29 | A | 110371.00 | Acquired | 2030-02-28 | Common Stock (110371.00) | Direct |
Footnotes
F1: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which begins March 28, 2020
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Investor Presentation
2026
Apr 13
Director's Dealing
2026
Mar 24
Legal Proceedings Report
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7